Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2010 by Translational Oncology Research International.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Genentech
Information provided by:
Translational Oncology Research International
ClinicalTrials.gov Identifier:
NCT00095706
First received: November 5, 2004
Last updated: July 26, 2010
Last verified: July 2010
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: No date given
  Primary Completion Date: April 2007 (Final data collection date for primary outcome measure)